drugset

drugset / Trial / NCT02396069

The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers

NCT02396069 ↗

Phase 1 Completed 24 enrolled Jeil Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

Double blind, randomized, placebo control, multiple dose, dose escalation study

Timeline

Start: 2015-03
Primary completion: 2015-08
Completion: 2015-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMELPARIB	Small molecule	—	Other

Indications